Reversing endogenous alloreactive B cell GC responses with anti-CD154 or CTLA-4Ig

Area of Science:

• Immunology
• Transplantation immunology
• Cellular immunology

Background:

• Alloantibodies are critical drivers of acute and chronic rejection in clinical transplantation.
• Understanding the cellular dynamics of alloreactive B cell activation and differentiation is crucial for improving transplant outcomes.

Purpose of the Study:

• To investigate the in vivo activation and differentiation of alloreactive B cells in response to allogeneic sensitization.
• To evaluate the efficacy of delayed blockade therapies in halting established alloantibody responses.

Main Methods:

• Utilized a modified MHC Class I tetramer staining technique for high-specificity tracking of Class I-specific B cells.
• Analyzed B cell populations in draining lymph nodes and spleen post-sensitization.
• Administered anti-CD40 or CTLA-4Ig blockade starting on Day 7 postimmunization.

Main Results:

• A significant increase (1.5- to 3.2-fold) in K(d)-binding B cells was observed by Day 7-8 post-sensitization.
• Within the K(d)-binding B cell population, distinct subsets with germinal center and plasma cell phenotypes were identified.
• Delayed blockade with anti-CD40 or CTLA-4Ig completely dissolved established germinal centers and halted alloantibody production.

Conclusions:

• MHC Class I tetramers are effective tools for tracking endogenous, Class I-specific B cells in vivo.
• Delayed therapeutic blockade targeting CD40 or CTLA-4Ig can effectively halt established allo-B cell responses and alloantibody production.